Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
Interim Analysis of the FIDES-01 Study
Read More
Cholangiocarcinoma
PROs from the TOPAZ-1 Study Evaluating Durvalumab plus GemCis in Advanced BTCs
Read More
Cholangiocarcinoma
Results from the Regional Subgroup Analysis of the TOPAZ-1 Study Evaluating Durvalumab plus GemCis in Advanced BTCs
Read More
Cholangiocarcinoma
Preliminary Results from the FIDES-01 Trial: Derazantinib as a Second-Line Treatment for iCCA with FGFR2 Alterations
Read More
Cholangiocarcinoma
Results from the Phase 2 NEO-GAP Trial: Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA
Read More
Cholangiocarcinoma
Early Data from the ReFocus Trial
Read More
Cholangiocarcinoma
TOPAZ-1 Trial Subanalysis: Outcomes by Primary Tumor Location in Advanced BTCs
Read More
Cholangiocarcinoma
Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC
Read More
Cholangiocarcinoma
Final Results from the FIGHT-202 Trial of Pemigatinib in Metastatic CCA
Read More
Cholangiocarcinoma
Results from the BilT-04 Study: First-Line GemCis with or without CPI-613 in Advanced BTCs
Read More
40
41
42
43
44
45
46
Page 43 of 196
Results 421 - 430 of 1953
